Cargando…

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

The adenovirus (Ad)26 serotype–based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector–based vaccines significantly influences antigen-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Selina, Salisch, Nadine C., Gil, Ana Izquierdo, Boedhoe, Satish, Boer, Karin Feddes-de, Serroyen, Jan, Schuitemaker, Hanneke, Zahn, Roland C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664441/ https://www.ncbi.nlm.nih.gov/pubmed/36379957 http://dx.doi.org/10.1038/s41541-022-00567-w

Ejemplares similares

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
por: Tiemessen, Machteld M., et al.
Publicado: (2022)

Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
por: Solforosi, Laura, et al.
Publicado: (2021)

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations
por: Salisch, N. C., et al.
Publicado: (2019)

Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform
por: Salisch, Nadine C., et al.
Publicado: (2017)

Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
por: van der Lubbe, Joan E. M., et al.
Publicado: (2021)

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
por: Saeland, Eirikur, et al.
Publicado: (2023)

Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques
por: Solforosi, Laura, et al.
Publicado: (2023)

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
por: Swart, Maarten, et al.
Publicado: (2023)

Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge
por: van der Lubbe, Joan E. M., et al.
Publicado: (2018)

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
por: van der Fits, Leslie, et al.
Publicado: (2020)

Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species
por: Zahn, Roland, et al.
Publicado: (2012)

Ligand conjugate SAR and enhanced delivery in NHP
por: Holland, Richard James, et al.
Publicado: (2021)

Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
por: Mahrokhian, Shant H., et al.
Publicado: (2022)

An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model
por: Bockstal, Viki, et al.
Publicado: (2018)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Understanding them to understand ourselves: The importance of NHP research for translational neuroscience
por: Lear, Annabella, et al.
Publicado: (2022)

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
por: Roozendaal, Ramon, et al.
Publicado: (2021)

In vivo imaging in NHP models of malaria: Challenges, progress and outlooks
por: Beignon, Anne-Sophie, et al.
Publicado: (2014)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

The Canadian Natural Health Products (NHP) Regulations: Industry Compliance Motivations
por: Laeeque, Hina, et al.
Publicado: (2007)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors
por: Laeeque, Hina, et al.
Publicado: (2006)

Soft Tissue Cephalometric Standards based on NHP in a Sample of Iranian Adults
por: Ahangar Atashi, Mohammad Hossein, et al.
Publicado: (2008)

Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model)
por: Broeckel, Rebecca, et al.
Publicado: (2015)

Common functional localizers to enhance NHP & cross-species neuroscience imaging research
por: Russ, Brian E, et al.
Publicado: (2021)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

The HMGB chromatin protein Nhp6A can bypass obstacles when traveling on DNA
por: Kamagata, Kiyoto, et al.
Publicado: (2020)

Evaluation of [(18)F]Favipiravir in Rodents and Nonhuman Primates (NHP) with Positron Emission Tomography
por: Rong, Jian, et al.
Publicado: (2023)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()
por: Custers, Jerome, et al.
Publicado: (2021)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
por: Dari, Anna, et al.
Publicado: (2023)

Single-molecule FRET analysis of DNA binding and bending by yeast HMGB protein Nhp6A
por: Coats, Julie E., et al.
Publicado: (2013)

Evidence for a bind-then-bend mechanism for architectural DNA binding protein yNhp6A
por: Sarangi, Manas Kumar, et al.
Publicado: (2019)

Efficacy of NHP66 Bioactive Cage on Patients with Cervical Spine Injury in Short-Track Speed Skating
por: Yang, Xinming, et al.
Publicado: (2022)

Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
por: He, Xuan, et al.
Publicado: (2021)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t251qh7hvrnkk7llbfgm6nguf5